Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Conditions
- COPD
- Interventions
- Other: Physiotherapy programDrug: Medical standard treatment
- Registration Number
- NCT02515318
- Lead Sponsor
- Universidad de Granada
- Brief Summary
Chronic Obstructive Pulmonary Disease (COPD) is projected to be the fifth leading burden of disease worldwide by the year 2020. An acute exacerbation of COPD (AECOPD) is defined as an acute event characterized by a worsening of the patient's respiratory symptoms that requires a modification in the medication. AECOPD are frequent (mean of 1-4 exacerbations each year). It increases in frequency with the severity of the disease. The objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients with COPD during hospitalization due to an acute exacerbation.
- Detailed Description
Chronic obstructive pulmonary disease (COPD) is one of the leading diseases causing mortality and morbidity, despite advanced pharmacotherapy and therapeutic management.
COPD patients suffer frequent exacerbations, defined as 'acute events characterized by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication'. Acute illness and prolonged bed rest are associated with loss of muscle mass and a significant decline in functional ability and mobility. Interventions to counteract these impairments are indicated.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- COPD diagnosis with exacerbation.
- No contraindication of physiotherapy.
- Signed written consent.
- Medical approval for inclusion
- Neurological, orthopedic or heart diseases.
- Prosthetic devices in the lower limbs.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Physiotherapy program Physiotherapy program Patients with COPD are included in this group. They will receive a physiotherapy program during the hospitalization due to acute exacerbation of COPD, additionally to the standard medical treatment Control group Medical standard treatment Patients with COPD are included in this group. They will receive the medical standard treatment during the hospitalization due to acute exacerbation of COPD.
- Primary Outcome Measures
Name Time Method Muscle strength Participants will be followed for the duration of hospital stay, an expected average of 9 days. Quadriceps strength will be assessed with a portable dynamometer. The test will be performed as previously reported
Exercise capacity Participants will be followed for the duration of hospital stay, an expected average of 9 days. Five times sit to stand test (5STS) will be used to assess exercise capacity, 5STS is a simple assessment tool that is feasible in all healthcare settings, and may be a rapid method of assessing changes in exercise capacity in COPD and screening for poor physical functioning individuals.
- Secondary Outcome Measures
Name Time Method Impact of COPD Participants will be followed for the duration of hospital stay, an expected average of 9 days. The impact of COPD in patient's life will be evaluated with COPD Assessment Test (CAT) that is a simple instrument to quantify chronic obstructive pulmonary disease (COPD) impact in routine practice.
Respiratory function Participants will be followed for the duration of hospital stay, an expected average of 9 days. Spirometry is regarded as the gold standard measure of respiratory function. Spirometry will be performed according to the American Thoracic Society criteria.
Fatigue Participants will be followed for the duration of hospital stay, an expected average of 9 days. Fatigue will be assessed with the Fatigue Severity Scale (FSS). The FSS is a nine-item instrument designed to assess fatigue as a symptom of a variety of different chronic conditions and disorders. The scale addresses fatigue's effects on daily functioning, querying its relationship to motivation, physical activity, work, family, and social life, and asking respondents to rate the ease with which they are fatigued and the degree to which the symptom poses a problem for them.
Dyspnea Participants will be followed for the duration of hospital stay, an expected average of 9 days. Dyspnea perception will be assessed with Borg modified scale. Patients will classify their breathlessness between 0 and 10.
Health status Participants will be followed for the duration of hospital stay, an expected average of 9 days. EuroQol-5D (EQ-5D) will be used to assess quality of life. EQ-5D is a generic questionnaire and consists of two parts, the EQ-5D Visual analogue scale (VAS) and the EQ-5D index. The EQ-5D VAS consists on a vertical rating scale from 0 to 100 (0 = death/worst possible health state and 100 = best possible health state). The EQ-5D index is a five-item questionnaire (mobility, self-care, usual activity, pain/discomfort and anxiety/depression). Each item has three levels: no problem, some problem and severe problem.
Trial Locations
- Locations (2)
University of Granada
🇪🇸Granada, Spain
Department of Physical Therapy
🇪🇸Granada, Spain